Vaccine

A third COVID-19 vaccine dose and its link to Long COVID risk in adults after initial vaccination

Updated

Abstract

Among 18,930 person-trials, long COVID incidence at 6 months was 0.9% for those receiving a third vaccine dose and 1.0% for those who did not.

  • At 6 months, the difference in long COVID incidence between those receiving a third dose and those not receiving it was -0.1%.
  • The risk ratio for long COVID incidence at 6 months was 0.93, suggesting no significant reduction with the third dose.
  • At 12 months, long COVID incidence was 4.9% for participants receiving a third dose compared to 4.5% for those who did not.
  • The risk difference at 12 months was 0.4%, with a risk ratio of 1.09, indicating no meaningful impact of the third dose on long COVID incidence.

Simplified

Full Text

Full text is available at the source.

Funding

Competing interests

Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Denis Nash reports financial support was provided by Gilead Sciences Inc. Denis Nash reports financial support was provided by AbbVie Inc. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free